Cubist Systematic Strategies, LLC - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 166 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Cubist Systematic Strategies, LLC ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$132,024
-96.6%
8,523
-96.5%
0.00%
-95.5%
Q1 2024$3,865,291
+408.1%
242,490
+435.8%
0.02%
+340.0%
Q4 2023$760,787
+212.8%
45,258
+117.5%
0.01%
+150.0%
Q3 2023$243,222
-92.3%
20,806
-89.0%
0.00%
-89.5%
Q1 2023$3,141,827
-49.2%
189,495
-43.0%
0.02%
-47.2%
Q4 2022$6,182,900
-24.9%
332,414
-48.2%
0.04%
-21.7%
Q3 2022$8,234,000
+231.3%
641,800
+81.0%
0.05%
+206.7%
Q2 2022$2,485,000
+0.0%
354,519
+18.3%
0.02%
-28.6%
Q1 2022$2,484,000
+7.3%
299,595
-12.3%
0.02%
-4.5%
Q4 2021$2,314,000
+288.9%
341,762
+204.6%
0.02%
+214.3%
Q3 2021$595,000
+72.5%
112,195
+86.8%
0.01%
+75.0%
Q2 2021$345,000
+148.2%
60,055
+99.1%
0.00%
+100.0%
Q1 2021$139,000
+32.4%
30,167
-3.7%
0.00%
+100.0%
Q4 2020$105,000
-11.0%
31,333
-20.8%
0.00%
-50.0%
Q3 2020$118,000
-35.9%
39,575
-0.5%
0.00%
-33.3%
Q2 2020$184,000
+80.4%
39,787
+46.6%
0.00%
+50.0%
Q4 2019$102,000
-67.5%
27,143
-66.8%
0.00%
-66.7%
Q2 2019$314,000
+912.9%
81,806
+537.4%
0.01%
+200.0%
Q1 2018$31,000
+40.9%
12,835
+11.6%
0.00%0.0%
Q1 2017$22,00011,5000.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Broadfin Capital, LLC 7,097,300$27,750,0004.54%
GREAT POINT PARTNERS LLC 3,817,288$14,926,0002.55%
TANAKA CAPITAL MANAGEMENT INC 256,593$1,003,0002.29%
Consonance Capital Management LP 4,473,607$17,492,0001.58%
Avoro Capital Advisors LLC 3,892,343$15,219,0000.99%
KNOTT DAVID M 380,110$1,486,0000.59%
EAM Investors, LLC 790,872$3,092,0000.55%
Ghost Tree Capital, LLC 550,000$2,151,0000.50%
EAM Global Investors LLC 251,647$984,0000.50%
MANGROVE PARTNERS IM, LLC 924,648$3,615,0000.49%
View complete list of CATALYST PHARMACEUTICALS INC shareholders